Provectus appoints special advisers to board of directors

Provectus Biopharmaceuticals announced in a press release that it has appointed Bruce Horowitz and Dominic Rodrigues as special advisers to its board of directors, to advise on financial and corporate strategy.

The clinical-stage oncology and dermatology biopharmaceutical company also has received an investment commitment of up to $2.5 million from Eric Wachter, PhD, co-founder and chief technology officer, outlined in an 8-K filing on Feb. 21, according to the release. The investment will be made as a loan, and the funds will be used for clinical development programs and corporate operations.

“The appointments of Bruce Horowitz and Dominic Rodrigues … will aid the board in creating a financial and corporate environment conducive to carrying out our development of PV-10, our investigational oncology drug, and PH-10, our investigational dermatology drug,” Alfred E. Smith IV, chairman of the board of Provectus, stated in the release.

Horowitz, managing director of Capital Strategists, LLC, has been an independent consult for Provectus for more than a decade, and Rodrigues is a chartered financial analyst and adjunct professor of finance in the Lee Business School at the University of Nevada, Las Vegas.

Reference: www.provectusbio.com